Myriad Genetics (MYGN) Tops Q4 EPS by 3c, provides guidance

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $196.6 million versus the consensus estimate of $194.8 million.

GUIDANCE:

Myriad Genetics sees FY2024 EPS of $0.00-$0.05, versus the consensus of ($0.02). Myriad Genetics sees FY2024 revenue of $820-840 million, versus the consensus of $834 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• HomeTrust to acquire Blue Ridge Bankshares in $448M all-stock deal
• The LGL Group (LGL) Misses Q2 EPS by 8c